Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.

Journal of Cancer·2025

Same author

Systemic Therapy for Melanoma: ASCO Guideline Update Q and A.

JCO oncology practice·2023

Same author

Systemic Therapy for Melanoma: ASCO Guideline Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).

Journal of translational medicine·2023

Same author

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Cancer chemotherapy and pharmacology·2023

Same author

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

Journal of translational medicine·2022

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Current systemic therapy for metastatic melanoma.

Sanjiv S Agarwala¹

¹St Luke's Cancer Center, University of Pennsylvania, Bethlehem, PA, USA. agarwas@slhn.org

Expert Review of Anticancer Therapy

|May 19, 2009

Summary

This summary is machine-generated.

Metastatic melanoma has few effective treatments, with limited long-term remission rates. Ongoing research focuses on novel immunotherapies and targeted treatments for this lethal skin cancer.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Experiment Videos

Last Updated: Jun 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Area of Science:

Oncology
Immunology
Dermatology

Background:

Metastatic melanoma is a deadly cancer with less than 10% long-term remission.
No new drugs have been approved for metastatic melanoma in over 20 years.
Current treatments like chemotherapy and chemo-immunotherapy show limited efficacy in trials.

Purpose of the Study:

To review the current status of treatments for metastatic melanoma.
To discuss recently completed and ongoing clinical trials.
To explore novel immunotherapeutic and targeted approaches.

Main Methods:

Literature review of completed and ongoing clinical trials.
Analysis of treatment efficacy and patient outcomes.
Discussion of novel therapeutic strategies.

Main Results:

High-dose interleukin-2 (IL-2) offers long-term remission in select patients but is impractical for most.
Chemotherapy and chemo-immunotherapy have not demonstrated significant advantages in randomized trials.
Research is actively exploring new immunotherapeutic and targeted treatment options.

Conclusions:

Metastatic melanoma treatment remains challenging with limited therapeutic options.
Novel immunotherapies and targeted therapies represent promising avenues for future research.
Continued investigation into clinical trials is crucial for advancing treatment strategies.